Comment from American College of Cardiology

Summary: The American College of Cardiology (ACC) supports the FDA's proposed pilot program to evaluate AI-enabled tools in early-phase clinical trials, recognizing their potential to improve efficiency and safety. However, they urge the FDA to implement rigorous standards for validation, transparency, human oversight, and bias assessment to ensure these tools do not compromise patient safety or scientific integrity.